Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Interferon and malignant disease--how does it work and why doesn't it always?

D Grandér1, S Einhorn

  • 1Department of Oncology-Pathology, Radiumhemmet, Karolinska Hospital, Stockholm, Sweden. dan@deptonc.ks.se

Acta Oncologica (Stockholm, Sweden)
|September 22, 1998
PubMed
Summary

Interferons (IFNs) are used in cancer therapy, but their effectiveness varies greatly. This review examines how IFNs fight tumors and why some patients do not respond to this treatment.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Irreversible TrxR1 inhibitors block STAT3 activity and induce cancer cell death.

Science advances·2020
Same author

PD-L1 is commonly expressed and transcriptionally regulated by STAT3 and MYC in ALK-negative anaplastic large-cell lymphoma.

Leukemia·2017
Same author

IL-6 activated JAK/STAT3 pathway and sensitivity to Hsp90 inhibitors in multiple myeloma.

Current medicinal chemistry·2014
Same author

MicroRNA-203 functions as a tumor suppressor in basal cell carcinoma.

Oncogenesis·2013
Same author

GCN5 acetylates and regulates the stability of the oncoprotein E2A-PBX1 in acute lymphoblastic leukemia.

Leukemia·2012
Same author

Glucocorticoid-induced cell death is mediated through reduced glucose metabolism in lymphoid leukemia cells.

Blood cancer journal·2012

Area of Science:

  • Oncology
  • Immunology
  • Biochemistry

Background:

  • Interferons (IFNs) have been utilized in clinical settings for nearly three decades as a therapeutic option for various malignancies.
  • While IFNs can induce remission in a subset of cancer patients, their efficacy is limited, offering no benefit or only marginal improvements for the majority.

Purpose of the Study:

  • To explore the potential mechanisms through which interferons exert their anti-tumor effects.
  • To investigate the reasons behind patient resistance to interferon therapy in the context of malignant diseases.

Main Methods:

  • Literature review of studies on interferon therapy in oncology.
  • Analysis of proposed molecular and cellular mechanisms of interferon action.
  • Examination of factors contributing to interferon resistance in cancer patients.

Related Experiment Videos

Main Results:

  • IFNs exhibit diverse anti-tumor activities through various pathways.
  • Significant inter-patient variability exists in response to IFN treatment.
  • Several mechanisms, including genetic mutations and immune evasion, can lead to IFN resistance.

Conclusions:

  • Understanding IFN's anti-tumor mechanisms is crucial for optimizing its use.
  • Identifying predictors of IFN resistance could lead to personalized treatment strategies.
  • Further research is needed to overcome resistance and improve outcomes for all cancer patients receiving IFN therapy.